Please assess the completion status of the following clinical trial:

Trial Title: Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hospitalized with acute HF (primary or secondary diagnosis) based on clinician assessment~2. A prior clinical diagnosis of HF (i.e., not a new diagnosis of heart failure during the current hospitalization)~3. Most recent LVEF ≤ 35% and within 6 months of randomization or LVEF ≤ 25% within 12 months of randomization~4. On optimal guideline-directed medical therapy for HFrEF (or previously deemed intolerant) as determined by the clinician including ACE-inhibitors or angiotensin receptor antagonists or neprilysin inhibition, aldosterone receptor antagonists, and maximally-tolerated doses of beta-blockers at the time of current evaluation (which may differ from long-term targets)~   * Maximally-tolerated doses of beta-blockers will be defined by the treating physician when considering aspects such as current dose relative to the target dose used in clinical trials, patient heart rate and blood pressure, and patient symptoms~  * Patients with intolerance or contraindication to beta-blocker use are eligible for enrollment (details will be documented in the case report form)~5. Age \>18 years~6. Willingness to provide informed consent from the subject (or their guardian or legally authorized representative \[LAR\])~7. On the day of planned randomization, all participants:~   * Must be in sinus rhythm with a resting heart rate \>70 bpm as measured on ECG or 10-second rhythm strip~  * Must have a blood pressure of \>90/50 mm Hg~Exclusion Criteria:~1. Documented plan for uptitration of beta-blocker in the following 4 weeks~2. Permanent atrial fibrillation or atrial flutter~3. Patients with recent atrial fibrillation or flutter defined by either precipitating the current HF hospitalization or occurring during the current HF hospitalization~4. History of untreated sick sinus syndrome, sinoatrial block, or second and third degree atrio-ventricular block~5. Pacemaker with atrial or ventricular pacing (except biventricular pacing) \>40% of the time~6. Family history or congenital long QT syndrome~7. Recent myocardial infarction (\<2 months prior to screening) \[troponin elevation secondary to acute HF as determined by the clinician is not an exclusion\]~8. Acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, INR \> 1.7 in the absence of anticoagulation treatment~9. Creatinine clearance \<15 mL/min within 48 hours of screening that was not due to acute kidney injury that resolved~10. Planned mechanical circulatory support within 180 days~11. Pregnant or breastfeeding women. Women with child-bearing potential should use effective contraception.~12. Medical conditions likely to lead to poor non-cardiac survival at 180 days (e.g., cancer)~13. Inability to comply with planned study procedures~14. If the following medications are needed at inclusion or during the study:~    * Non-dihydropyridine calcium channel blockers (e.g., diltiazem and verapamil)~   * Class I anti-arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin)~   * Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some macrolide antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, antiretroviral drugs (e.g., ritonavir, nelfinavir), and systemic azole antifungal agents (e.g., ketoconazole, itraconazole), and nefazodone~   * Inducers of cytochrome P450 3A4 (CYP3A4) including St. John's wort, rifampicin, barbiturates, and phenytoin.~   * Treatments known to be associated with significant prolongation of the QT interval, including sotalol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ivabradine (Type: ACTIVE_COMPARATOR): Active Comparator: ivabradine
- usual care (Type: PLACEBO_COMPARATOR): Placebo Comparator: usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).